Login to Your Account

Other News To Note

Thursday, October 18, 2012

• ElexoPharm GmbH, of Saarbruecken, Germany, said it will perform lead finding and lead optimization based on molecular modeling, design and synthesis of biological active compounds, under a EuroTransBio grant of €1.5 million (US$1.98 million). The three-year project will allow the development of low-molecular-weight inhibitors of angiogenesis in colorectal cancer in collaboration with SomantiX BV, VU University Medical Center, Saarland University and PharmBioTec GmbH.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription